Raphy
Gilles Raphy, Brussels BE
Patent application number | Description | Published |
---|---|---|
20100298289 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS - The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 11-25-2010 |
Gilles Raphy, Stortford GB
Patent application number | Description | Published |
---|---|---|
20100035863 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions - The present invention concerns novel 2 amino pyrimidine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as harmaceuticals. | 02-11-2010 |
Gilles Raphy, Essex GB
Patent application number | Description | Published |
---|---|---|
20120077815 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors - A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 03-29-2012 |
20120095005 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors - A series of substituted pyrazolo[1,5-α][1,3,5]triazine and pyrazolo[1,5-αj-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I). | 04-19-2012 |
Gilles Raphy, Chesterford Research Park GB
Patent application number | Description | Published |
---|---|---|
20130012515 | Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors - A series of fused bicyclic pyridine and pyrazine derivatives, substituted directly on the pyridine or pyrazine ring by a functional group attached via a sulphur-containing linkage, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 01-10-2013 |
Gilles Raphy, Saffron Walden Essex GB
Patent application number | Description | Published |
---|---|---|
20130012517 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors - A series of quinoline and quinoxaline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 01-10-2013 |
20130018057 | Quinoline and Quinoxaline Derivatives as Kinase InhibitorsAANM Burli; RolandAACI Saffron Walden EssexAACO GBAAGP Burli; Roland Saffron Walden Essex GBAANM Haughan; Alan FindlayAACI Saffron Walden EssexAACO GBAAGP Haughan; Alan Findlay Saffron Walden Essex GBAANM Matteucci; M zioAACI Saffron Walden EssexAACO GBAAGP Matteucci; M zio Saffron Walden Essex GBAANM Owens; Andrew PateAACI Saffron Walden EssexAACO GBAAGP Owens; Andrew Pate Saffron Walden Essex GBAANM Raphy; GillesAACI Saffron Walden EssexAACO GBAAGP Raphy; Gilles Saffron Walden Essex GBAANM Sharpe; AndrewAACI Saffron Walden EssexAACO GBAAGP Sharpe; Andrew Saffron Walden Essex GB - A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 01-17-2013 |
Gilles Raphy, Saffron Walden GB
Patent application number | Description | Published |
---|---|---|
20160024019 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF - Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. | 01-28-2016 |